Merck Places U.S. Bond Amounting to US$ 4.0 Billion
Placement is an important element of the financing of the proposed acquisition of Sigma-Aldrich
A total of five tranches were placed, comprising floating rate and fixed rate notes. The floating rate notes have a maturity of 2 years (US$ 250 million with a 0.35% spread over 3-month U.S. dollar LIBOR). The fixed rate notes have a maturity of 3 years (US$ 400 million with a coupon of 1.70%), 5 years (US$ 750 million with a coupon of 2.40%), 7 years (US$ 1.0 billion for 2.95%), and 10 years (US$ 1.6 billion for 3.25%).
“This first U.S. bond in Merck’s history shows that with our conservative financial policy, Merck is an attractive name for investors also outside Europe. In addition, the bond is an extremely important element of the financing of the proposed acquisition of Sigma-Aldrich. The strong resonance is very encouraging and is enabling us to further diversify our investor base,” said Marcus Kuhnert, Chief Financial Officer of Merck.
The bond achieved a well-diversified distribution among a wide range of institutional investors such as fund managers, insurance companies, pension funds, and banks. Bookrunners of the transaction were Merck’s relationship banks.
In December 2014, Merck had already successfully issued a euro hybrid bond amounting to € 1.5 billion. Merck is rated A flat (negative outlook) by Standard & Poor’s and Baa1 (negative outlook) by Moody’s.
The proposed acquisition of the laboratory supplier Sigma-Aldrich for US$ 17 billion is part of the “Fit for 2018” transformation and growth program, which aims to sustainably strengthen the company’s three growth platforms – Healthcare, Life Science and Performance Materials. Merck continues to expect the transaction to close in mid-2015.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.